Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5380952 | 1.00 | APP (0.37) | APPALDH1A1MAOBMTNR1AMTNR1B | |
| SCHEMBL5384650 | 0.85 | ALDH2 (0.43) | ALDH1A1MAOBDPP4KMT2AGAA | |
| SCHEMBL5384644 | 0.85 | ALDH2 (0.43) | ALDH1A1MAOBDPP4KMT2AGAA | |
| SCHEMBL5389865 | 0.85 | ALDH2 (0.43) | ALDH1A1MAOBDPP4KMT2AGAA | |
| Hydrochloric Acid SCHEMBL6231512 | 0.84 | ALDH2 (0.42) | ALDH1A1MAOBDPP4KMT2AGAA | |
| Hydrochloric Acid SCHEMBL6231515 | 0.84 | ALDH2 (0.42) | ALDH1A1MAOBDPP4KMT2AGAA | |
| SCHEMBL14446992 | 0.84 | L3MBTL1 (0.48) | ALDH1A1MAOBKMT2ATDP1MAPT | |
| SCHEMBL5388674 | 0.76 | TRPA1 (0.52) | APPGAASMN1; SMN2 | |
| SCHEMBL5389947 | 0.76 | TRPA1 (0.52) | APPGAASMN1; SMN2 | |
| SCHEMBL13141225 | 0.76 | LOXL2 (0.42) | ALDH1A1MAOBMAPTLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1373258-B1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PROD INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050049258-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| US-6828333-B2 | Treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| EP-1373258-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030027845-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2003-02-06 | — | — | US | disclosed |
| WO-2002060896-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | APP 4839/4885ALDH1A1 424/4885MAOB 322/4885 |
| US-20050049258-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | PDE4A, PDE4B, PDE3B | APP 4834/4885ALDH1A1 411/4885MAOB 254/4885 |
| US-20030027845-A1 | Ether derivatives useful as inhibitors of PDE4 isozymes | CBR1, PDE4A, PDE4B | APP 4778/4885ALDH1A1 474/4885MAOB 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.